Physician profile
Blane Eldon Snodgrass
NPI 1104816289
$6,736.73
in general payments reported to CMS, 2019-2025
19 companies · $835 in 2025
The $835 reported for 2025 was more than what 88% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $1,342 · 2021: $1,519 · 2022: $1,052 · 2023: $268 · 2024: $818 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,983.72 | 2019-2025 | Total30, Precision7, Dailies |
| Johnson & Johnson Vision Care, INC. | $998.75 | 2019-2022 | |
| Allergan, INC. | $914.53 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $518.67 | 2019-2024 | |
| Abbvie INC. | $443.56 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $290.60 | 2021-2023 | |
| Tarsus Pharmaceuticals, INC. | $245.44 | 2024-2025 | Xdemvy |
| The Cameron-Ehlen Group, INC. | $241.14 | 2020-2021 | |
| Shire North American Group INC | $186.58 | 2019 | |
| Kala Pharmaceuticals, INC. | $175.60 | 2020-2021 | |
| Coopervision INC. | $146.11 | 2019-2023 | Myday Contact Lens |
| Harrow Eye, LLC | $121.05 | 2025 | Vevye |
| Dompe US, INC. | $114.89 | 2021 | |
| Bausch & Lomb Americas INC. | $101.29 | 2022-2024 | Infuse, Biotrue One Day, Vyzulta |
| Mallinckrodt Hospital Products INC. | $99.99 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $73.92 | 2022 | |
| Eyevance Pharmaceuticals LLC | $33.10 | 2019-2020 | |
| Oyster Point Pharma, INC. | $28.04 | 2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Blane Snodgrass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.